Swiss Medical Equipment Stock News

Sika (SWX:SIKA) has wrapped up FY 2025 with Q4 revenue of CHF 2.6b and net income of CHF 174.1m, while Q4 basic EPS came in at CHF 1.09. Over the past few quarters, the company has reported revenue of CHF 2.8b and EPS of CHF 2.02 in Q4 2024, CHF 2.9b in Q3 2025, and CHF 2.6b in Q4 2025. This sets up a results season where investors are likely to focus on how these changes in revenue and EPS relate to margins. See our full analysis for Sika. With the latest figures on the table, the next step...

EFG International (SWX:EFGN) has reported its FY 2025 results with second half revenue of CHF 864.5 million and basic EPS of CHF 0.34, alongside net income excluding extra items of CHF 112.8 million. The group has seen revenue move from CHF 753.4 million and basic EPS of CHF 0.49 in the second half of 2024 to CHF 793.8 million and basic EPS of CHF 0.71 in the first half of 2025. Trailing twelve month revenue of CHF 1.66 billion and basic EPS of CHF 1.03 set the broader context for today’s...

If you are wondering whether Novartis shares still offer value at current levels, this article walks through what the numbers say about the price you are paying versus what you are getting. The stock last closed at $126.48, with returns of 2.2% over 7 days, 10.7% over 30 days, 16.6% year to date, 35.5% over 1 year, 85.7% over 3 years and 104.7% over 5 years. This naturally raises questions about how much of the story is already reflected in the price. Recent headlines around Novartis have...

Cosmo Pharmaceuticals (SWX:COPN) has drawn attention after a strong share price move in recent months, prompting investors to look more closely at how its gastroenterology, dermatology, and healthtech portfolio lines up with current expectations. See our latest analysis for Cosmo Pharmaceuticals. At a share price of CHF122.6, Cosmo Pharmaceuticals has logged a 9.66% 1 month share price return and an 81.90% 3 month share price return. The 1 year total shareholder return of 89.84% suggests...

As European markets experience volatility amid global concerns over AI disruptions, the pan-European STOXX Europe 600 Index has managed to hit new highs, reflecting resilience in the face of these challenges. In this environment, dividend stocks can offer a measure of stability and income potential for investors seeking to navigate uncertain times.

This article is designed to help you think clearly about whether Alcon's current share price fairly reflects its potential or if the market might be mispricing it. Alcon closed at $61.90, with a 1.4% gain over the last 7 days, a 3.2% decline over 30 days, a 2.6% decline year to date, and a 23.6% decline over the past year, which may catch the eye of investors reassessing the balance between opportunity and risk. Recent headlines around Alcon have focused on its position within healthcare and...

As European markets navigate volatility amid AI disruption concerns and digest strong U.S. job data, the pan-European STOXX Europe 600 Index managed to hit a new high, reflecting resilience in the region's economy. In such an environment, dividend stocks can offer investors a measure of stability and income potential, making them an attractive consideration for those looking to balance growth with steady returns.

If you are wondering whether ABB is still fairly priced after a strong run, this article will walk through what the current share price might be implying about value. ABB's share price closed at CHF 69.80, with returns of 1.7% over 7 days, 13.3% over 30 days, 14.0% year to date, 34.5% over 1 year, 139.7% over 3 years and 215.6% over 5 years. This raises the question of what is already reflected in the price. Recent news around ABB has focused on its position as a global industrial technology...

In early February 2026, Novartis reported final Phase III ALIGN data showing Vanrafia® (atrasentan) slowed kidney function decline in adults with IgA nephropathy, alongside a new long-term Actinium-225 supply agreement from Niowave to support its radioligand therapy portfolio for difficult-to-treat cancers. Together, these updates highlight Novartis’ effort to build depth in both renal disease and radiopharmaceutical oncology, reinforcing the importance of specialized therapies and secure...

As European markets navigate volatility, with the STOXX Europe 600 Index recently hitting a new high before settling nearly unchanged, investors are keenly observing economic indicators such as employment growth and GDP expansion in the eurozone. Amidst these dynamics, dividend stocks have gained attention for their potential to provide steady income; qualities like strong cash flow and a history of consistent payouts can make them appealing choices in uncertain market conditions.

The market seemed underwhelmed by the solid earnings posted by Schindler Holding AG ( VTX:SCHN ) recently. Our analysis...

In February 2026, Lindt & Sprüngli confirmed the return of its sold‑out DubaiStyle Chocolate to Canadian shelves, reintroducing the 150g bar and adding a new 40g snackable format crafted with smooth milk chocolate, pistachio filling and kadayif pastry. The launch of a portable 40g DubaiStyle bar alongside the original 150g format highlights how Lindt is using premium, culturally inspired recipes to broaden everyday indulgence occasions. We’ll now examine how expanding DubaiStyle into a new...

As European markets experience volatility amidst global concerns about AI disruption and economic data releases, the pan-European STOXX Europe 600 Index has managed to reach new highs, reflecting a complex investment landscape. In such an environment, dividend stocks can offer a measure of stability and income potential for investors seeking to navigate these uncertain times.

Board overhaul puts Lonza Group (SWX:LONN) governance in focus Lonza Group (SWX:LONN) has set out a broad board refresh, nominating tech-focused leader Sami Atiya and proposing Claudia Süssmuth-Dyckerhoff as Vice-Chair while several long-serving directors prepare to step down. See our latest analysis for Lonza Group. The board refresh headlines come at a time when Lonza Group’s 1-day share price return of 1.19% and 7-day share price return of 2.21% sit against a 1-year total shareholder...

ABB (SWX:ABBN) is back in focus after reporting strong Q4 results, growing orders, and outlining a CHF2.0b share buyback, alongside new contract wins in power and data centre electrification. See our latest analysis for ABB. ABB’s recent Q4 update, the CHF2.0b share buyback and new electrification contracts have arrived alongside a 30 day share price return of 13.6% and a 1 year total shareholder return of 37.6%. Together these developments point to strengthening momentum rather than a short...

Idorsia (SWX:IDIA) is back on investors’ radar after securing regulator alignment in the US and Europe on a streamlined Phase 3 registration program for its Fabry disease candidate, lucerastat. See our latest analysis for Idorsia. The latest lucerastat update lands after a sharp swing in sentiment, with Idorsia’s 1 year total shareholder return very large at about 5.3x. However, the year to date share price return is slightly negative and longer term total shareholder returns over 3 and 5...

With a median price-to-earnings (or "P/E") ratio of close to 21x in Switzerland, you could be forgiven for feeling...

Key Insights Significant insider control over Ypsomed Holding implies vested interests in company growth H. C. Michel...

Accelleron Industries has announced a major reshaping of its Board of Directors, proposing Monika Krüsi as Chairwoman and adding Mieke Van de Capelle, while two current directors step down early as part of an accelerated succession plan ahead of the 28 April 2026 AGM. This governance renewal could recalibrate how the company sets priorities in areas such as nomination, compensation, and sustainability oversight, potentially influencing its long-term direction. We’ll now examine how this...

Recent performance and context for UBS Group shares UBS Group (SWX:UBSG) has drawn investor attention after a monthly return of about a 16% decline and a 3‑month gain of roughly 4%, set against a backdrop of mixed shorter-term price moves. See our latest analysis for UBS Group. At a share price of CHF32.10, UBS Group’s recent 1 month share price return of a 16% decline and 7 day share price return of a 5% decline contrast with a 1 year total shareholder return of 9.8% and 5 year total...

It's been a good week for Swisscom AG ( VTX:SCMN ) shareholders, because the company has just released its latest...

There wouldn't be many who think Sonova Holding AG's ( VTX:SOON ) price-to-earnings (or "P/E") ratio of 22.7x is worth...

Key Insights Burckhardt Compression Holding's significant retail investors ownership suggests that the key decisions...

When you buy a stock there is always a possibility that it could drop 100%. But on the bright side, you can make far...